JP2019509014A - Ｃｄ３９血管アイソフォームターゲティング剤 - Google Patents

Ｃｄ３９血管アイソフォームターゲティング剤 Download PDF

Info

Publication number
JP2019509014A
JP2019509014A JP2018526708A JP2018526708A JP2019509014A JP 2019509014 A JP2019509014 A JP 2019509014A JP 2018526708 A JP2018526708 A JP 2018526708A JP 2018526708 A JP2018526708 A JP 2018526708A JP 2019509014 A JP2019509014 A JP 2019509014A
Authority
JP
Japan
Prior art keywords
optionally
antibody
amino acid
residue
kabat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018526708A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509014A5 (enExample
Inventor
ジェレミー・バスティド
ローラン・ゴーティエ
カリーヌ・パトゥレル
イヴァン・ペロ
アラン・ルセル
ベアトリス・アミグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of JP2019509014A publication Critical patent/JP2019509014A/ja
Publication of JP2019509014A5 publication Critical patent/JP2019509014A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018526708A 2015-11-23 2016-11-22 Ｃｄ３９血管アイソフォームターゲティング剤 Pending JP2019509014A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562258701P 2015-11-23 2015-11-23
US62/258,701 2015-11-23
US201562263760P 2015-12-07 2015-12-07
US62/263,760 2015-12-07
US201562267343P 2015-12-15 2015-12-15
US62/267,343 2015-12-15
US201662320738P 2016-04-11 2016-04-11
US62/320,738 2016-04-11
US201662404779P 2016-10-06 2016-10-06
US62/404,779 2016-10-06
PCT/EP2016/078395 WO2017089334A1 (en) 2015-11-23 2016-11-22 Cd39 vascular isoform targeting agents

Publications (2)

Publication Number Publication Date
JP2019509014A true JP2019509014A (ja) 2019-04-04
JP2019509014A5 JP2019509014A5 (enExample) 2019-12-12

Family

ID=57391960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526708A Pending JP2019509014A (ja) 2015-11-23 2016-11-22 Ｃｄ３９血管アイソフォームターゲティング剤

Country Status (6)

Country Link
US (1) US20190153113A1 (enExample)
EP (1) EP3380519A1 (enExample)
JP (1) JP2019509014A (enExample)
AU (1) AU2016359790A1 (enExample)
CA (1) CA3005986A1 (enExample)
WO (1) WO2017089334A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022545585A (ja) * 2019-08-27 2022-10-28 エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド 新規の抗ｃｄ３９抗体
JP2025508956A (ja) * 2022-03-03 2025-04-10 アーカス バイオサイエンシズ インコーポレイティド 抗ｃｄ３９抗体及びその使用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3153526B1 (en) 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
AU2018235092B2 (en) 2017-03-16 2024-09-19 Innate Pharma Compositions and methods for treating cancer
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
SG11202000820PA (en) * 2017-07-31 2020-02-27 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
AU2018346447B2 (en) * 2017-10-06 2025-06-19 Innate Pharma Restoration of T cell activity via the CD39/CD73 axis
IL273440B1 (en) * 2017-11-15 2026-08-01 Innate Pharma Strengthening the effect of ATP release
JP7800852B2 (ja) * 2018-01-10 2026-01-16 バイオインヴェント インターナショナル アーベー 抗体の新規組み合わせおよびその使用
CN112074541A (zh) 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3806902A4 (en) * 2018-06-14 2022-05-04 Beth Israel Deaconess Medical Center, Inc. COMPOSITIONS AND METHODS TO PREVENT OR REVERSE T-CELL DEPLETION BY ECTONUCLEOTIDASE INHIBITION AND ANTIBODY-MEDIATED TARGET CYTOSIS
TWI870353B (zh) 2018-06-18 2025-01-21 法商天賜製藥公司 用於治療癌症之組合物及方法
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
KR20220002959A (ko) 2019-04-23 2022-01-07 이나뜨 파르마 에스.에이. Cd73 차단 항체
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
US12391756B2 (en) 2019-11-05 2025-08-19 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for CD39 and use thereof
TW202307006A (zh) * 2021-06-03 2023-02-16 美商表面腫瘤學公司 用抗ｃｄ３９抗體及派姆單抗治療癌症之方法
CA3248580A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS CAUSED BY EOSINOPHIL ACTIVITY
WO2024115935A1 (en) * 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510953A (ja) * 2008-01-31 2011-04-07 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 制御性ｔ細胞活性を抑制するための、ヒトｃｄ３９に対する抗体およびその使用
WO2012085132A1 (en) * 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
JP2014523408A (ja) * 2011-06-06 2014-09-11 ノヴォ ノルディスク アー／エス 治療抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510953A (ja) * 2008-01-31 2011-04-07 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 制御性ｔ細胞活性を抑制するための、ヒトｃｄ３９に対する抗体およびその使用
WO2012085132A1 (en) * 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
JP2014523408A (ja) * 2011-06-06 2014-09-11 ノヴォ ノルディスク アー／エス 治療抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MALISZEWSKI CR. ET AL.: "The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization", THE JOURNAL OF IMMUNOLOGY, vol. 153(8), JPN6020035462, 1994, pages 3574 - 3583, ISSN: 0004564635 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022545585A (ja) * 2019-08-27 2022-10-28 エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド 新規の抗ｃｄ３９抗体
US12312410B2 (en) 2019-08-27 2025-05-27 Elpiscience (Suzhou) Biopharma, Ltd Anti-CD39 antibodies
JP7727387B2 (ja) 2019-08-27 2025-08-21 エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド 新規の抗ｃｄ３９抗体
JP2025508956A (ja) * 2022-03-03 2025-04-10 アーカス バイオサイエンシズ インコーポレイティド 抗ｃｄ３９抗体及びその使用
JP7712496B2 (ja) 2022-03-03 2025-07-23 アーカス バイオサイエンシズ インコーポレイティド 抗ｃｄ３９抗体及びその使用

Also Published As

Publication number Publication date
EP3380519A1 (en) 2018-10-03
WO2017089334A1 (en) 2017-06-01
US20190153113A1 (en) 2019-05-23
CA3005986A1 (en) 2017-06-01
AU2016359790A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
JP7132981B2 (ja) Ｃｄ７３遮断
US20230340143A1 (en) Compositions and methods for treating cancer
US20190153113A1 (en) Cd39 vascular isoform targeting agents
US20220056145A1 (en) Anti-cd39 antibodies
KR102826033B1 (ko) 암을 치료하기 위한 조성물 및 방법
EP3377529B1 (en) Siglec-10 antibodies
RU2781116C1 (ru) Составы и способы для лечения рака
HK40040395B (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191018

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200923

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220215